eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platform includes mRNA construct design and optimization, proprietary lipid nanoparticles (LNP) and formulations, and in-house process engineering capabilities for mRNA drug substance manufacturing. eTheRNA’s technology platforms are poised to transform mRNA drug development by providing our partners with proprietary solutions that address many of the major challenges in mRNA drug development, including: Insufficient immune response resulting in suboptimal efficacy, Suboptimized lipid nanoparticle (LNP) formulations, Lack of drug product thermostability, Limited global access to mRNA products and production. eTheRNA anticipates entering a robust period of business development and licensing activities as our technology platforms become more widely known and further validated.